Scientific Advisor


Dr. Tasian is a pediatric oncologist and physician-scientist at the Children’s Hospital of Philadelphia and University of Pennsylvania who is interested in development of molecularly-targeted therapeutics for children with high-risk leukemias.

Her translational laboratory research program focuses upon testing of kinase inhibitors and chimeric antigen receptor (CAR) T cell immunotherapies in genetic subsets of childhood ALL and AML.

Dr. Tasian has leadership roles in the Children’s Oncology Group (COG) ALL and Myeloid Diseases committees, is the COG Developmental Therapeutics committee Vice-Chair of Biology for Hematologic Malignancies, and leads or co-leads several national or institutional early phase clinical trials testing precision medicine therapies in children with high-risk leukemias.